Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients;Faktory predikující selhání adjuvantní hormonoterapie u karcinomu prsu, studované na souboru pacientek léčených tamoxifenem

Klinicka Onkologie

Volumn 21, Issue 5, 2008, Pages 303-308

  Petráková, Katarína ^a   Nenutil, R ^a   Grell, P ^a   Fabian, P ^a   Zichova I ^a   Svoboda, M ^a   Palacova M ^a   Vyzula, R ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Breast cancer; Cyclin D1; Disease free survival; Her 2 genes; Progesterone; Receptors; Tamoxifen

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MOLECULAR MARKER; PARAFFIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; HORMONE RESISTANCE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE NEU; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIMARY TUMOR; RISK ASSESSMENT; RISK FACTOR; TISSUE MICROARRAY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 58149278847     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Early Breast Cancer Trialists' Collaborative Group 1998. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
2. De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty year results of the Naples GUN Randomised Trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003;9:1039-1046.
3. Dowsett M, Houghton J, Iden C, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006;17(5):818-26.
4. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
5. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741-4748.
6. Goldhirsch A, Wood W.C, Gelber R.D, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-1144.
7. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.
8. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97:1254-61.
9. Ormandy CJ, Musgrove EA, Hui R, et al. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003;78:323-335.
10. Fu M, Wang C, Li Z, et al. Cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-5447.
11. Van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000;6(6):2138-45.
12. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase.Nature 2000 Sep 28;407(6803):538-41.
13. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinasa/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-9824.
14. Petráková K, Nenutil R, Vyskočil J, et al. Adding the estimation of cyclin D1 gene amplification to the standard panel of predictors in breast carcinoma can significantly imrpove identification of the tumors resistant to tamoxifen. Breast Cancer Res Treat 2007; 106 Suppl 1 Abstract 2O19
15. Coates AS, Keshaviah A, Thürlimann B, etal. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. JCO 2007;10:486-492.
16. Forbes J, Cuzick J, Buzdar A, et al. ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen. Breast Cancer Res Treat 2007; 106 Suppl 1 Abstract 41: 12-13.